Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

Green, Jane; Czanner, Gabriela; Reeves, Gillian; Watson, Joanna; Wise, Lesley; Beral, Valerie

doi:10.1136/bmj.c4444

Cited by 244 publications

(214 citation statements)

References 26 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Predicated upon a series of case reports, the Medicines and Healthcare Products Regulatory Agency sought to evaluate this issue by means of an epidemiological study. 58 The results suggested that fi ve years or more of bisphosphonate therapy was associated with a small absolute increase in the risk of oesophageal cancer among men and women aged between 60-79 years. 58 While others have not observed this increased risk, the spectre of this association has yet to be defi nitively excluded.…”

Section: Bisphosphonatesmentioning

confidence: 91%

Drug therapies in older adults (part 1)

Mukhtar

Jackson

2015

Clinical Medicine

View full text Add to dashboard Cite

Prescribing for older adults represents a signifi cant challenge as the UK population ages. Physiological decline and the rising prevalence of frailty increase the likelihood of altered pharmacodynamics and pharmacokinetics, suboptimal prescribing and adverse effects among this growing cohort of the population. In the fi rst of two articles, we begin by considering these issues and posit four key questions which should be considered when prescribing for older adults. Does this agent refl ect the priorities of the patient? Are there alternatives -with greater effi cacy, effectiveness or tolerability -that might be considered? Are the dose, frequency and formulation appropriate? How does this prescription relate to concurrent medication? We also describe current drug therapies in two disease states with a predilection for older adults: Alzheimer's disease (AD) and osteoporosis. Using these examples we highlight the limitations of evidencebased medicine and guidelines in this cohort of the population, illustrating the reliance on sub-group analysis to demonstrate the effi cacy of drug therapies for older adults in osteoporosis and the underutilisation of appropriate treatments for patients with AD as a result of fl awed guidelines.

show abstract

Section: Bisphosphonatesmentioning

confidence: 91%

Drug therapies in older adults (part 1)

Mukhtar

Jackson

2015

Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…Yapılan çalışmalarda, nonvertebral kırıkları %39 oranında, kalça kırığı riskini ise %40-60 oranında azalttığı saptanmıştır. 33 İ İb ba an nd dr ro on na at t: : Bisfosfonatlar içerisinde yalnızca ibandronatın erkek osteoporozunda endikasyonu yoktur. Kalça kırığı ile ilgili verisi de yetersizdir.…”

Section: Farmakoloji̇k Tedavi̇unclassified

“…Bu nedenle bisfosfonatların oral kullanımı Barret özofagusu, özofageal reflü, akalazya ve hiatus hernisi olan hastalara öne-rilmemektedir. 33 Parenteral bisfosfonatlarda da GİS irritasyonu dışındaki diğer yan etkiler gözlenebil-mektedir. Renal toksisite oral bisfosfonatlar ile çok nadir olsa da özellikle parenteral bisfosfonat kullanımından sonra renal fonksiyonların takibine dikkat edilmelidir.…”

Section: Farmakoloji̇k Tedavi̇unclassified

Osteoporosis: Screening, Prevention and Treatment: Review

Cengiz¹,

Yürüyen²

2016

Turkiye Klinikleri J Intern Med

View full text Add to dashboard Cite

“…The possible association between use of oral bisphosphonates and risk of cancer of the esophagus is currently being reviewed by the FDA. The two largest epidemiologic studies looking at this association were both published in 2010 looking at the same database of patients but came to conflicting results [3,4]. Other side effects of bisphosphonates include renal insufficiency, ocular complaints, hypocalcemia, osteonecrosis of the jaw, atypical fractures of the femur, and possibly an increased risk of atrial fibrillation.…”

Section: Failures Of Bisphosphonate Therapymentioning

confidence: 99%

Medical Management of Osteoporosis When Bisphosphonates Fail

Friedman

Eslami

2013

Curr Transl Geriatr Exp Gerontol Rep

View full text Add to dashboard Cite

Osteoporosis is a systemic skeletal disease characterized by low bone mass, bone fragility and subsequent increased risk for fractures. Bisphosphonates are the most commonly prescribed drug for treatment of osteoporosis, and they have been shown to be effective in reducing risk of vertebral, nonvertebral, and hip fractures. Some patients, however, are not good candidates for bisphosphonate therapy, either due to comorbities such as renal insufficiency, or due to ongoing fractures despite therapy. In either case, multiple other agents can be used to treat osteoporosis. In this article we will review the FDA-approved therapies to treat osteoporosis other than bisphosphonates, and we will highlight the most recent clinical trials evaluating the efficacy of these various agents.

show abstract

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

Cited by 244 publications

References 26 publications

Drug therapies in older adults (part 1)

Drug therapies in older adults (part 1)

Osteoporosis: Screening, Prevention and Treatment: Review

Medical Management of Osteoporosis When Bisphosphonates Fail

Contact Info

Product

Resources

About